Carisma Therapeutics (CARM) Price & Analysis

Q: What was Carisma Therapeutics’s price range in the past 12 months?

Carisma Therapeutics lowest stock price was $0.03 and its highest was $1.27 in the past 12 months.

Q: What is Carisma Therapeutics’s market cap?

Carisma Therapeutics’s market cap is $2.22M.

Q: When is Carisma Therapeutics’s upcoming earnings report date?

Carisma Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is 38 days ago.

Q: How were Carisma Therapeutics’s earnings last quarter?

Carisma Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.14.

Q: Is Carisma Therapeutics overvalued?

According to Wall Street analysts Carisma Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Carisma Therapeutics pay dividends?

Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here

Q: What is Carisma Therapeutics’s EPS estimate?

Carisma Therapeutics’s EPS estimate is -0.12.

Q: How many shares outstanding does Carisma Therapeutics have?

Carisma Therapeutics has 41,845,078 shares outstanding.

Q: What happened to Carisma Therapeutics’s price movement after its last earnings report?

Carisma Therapeutics reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -2%.

Q: Which hedge fund is a major shareholder of Carisma Therapeutics?

Currently, no hedge funds are holding shares in CARM

Compare

1,727 Followers

CARM Stock Chart & Stats

$0.06

-$0.04(-7.53%)

At close: Jan 08 4:00 PM EST

$0.06

-$0.04(-7.53%)

Day’s Range― - ―

52-Week Range$0.03 - $1.27

Previous CloseN/A

Volume72.54K

Average Volume (3M)2.25M

Market Cap

$2.22M

Enterprise Value$16.07M

Total Cash (Recent Filing)$2.78M

Total Debt (Recent Filing)$762.00K

Price to Earnings (P/E)0.3

Beta2.01

Next Earnings

Nov 06, 2025

EPS Estimate

-0.12

Last Dividend Ex-Date

Mar 08, 2023

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.23

Shares Outstanding41,845,078

10 Day Avg. Volume3,913,183

30 Day Avg. Volume2,245,153

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)-0.62

Price to Sales (P/S)0.88

P/FCF Ratio-0.29

Enterprise Value/Market Cap7.24

Enterprise Value/Revenue2.18

Enterprise Value/Gross Profit2.53

Enterprise Value/Ebitda1.18

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe mesothelin targeted autologous CAR monocyte program is expected to show evidence of clinical responses and clean safety, which should de-risk and validate the monocyte platform.

Strategic PartnershipsCarisma will focus on developing off-the-shelf products using its in vivo macrophage engineering platform, including those under the Moderna partnership.

Bears Say

Program DiscontinuationCarisma Therapeutics announced that it would be discontinuing development of its lead program, CT-0525.

Workforce ReductionAs part of the strategic restructuring, Carisma will reduce its workforce by 34%.

Carisma Therapeutics News

Carisma Therapeutics announces Nasdaq delisting, SEC deregistration

Carisma Therapeutics (CARM)’ Board of Directors has approved and the Company intends to proceed with the voluntary delisting...

9d ago

CARM

Carisma Therapeutics Announces Nasdaq Delisting and Leadership Changes

The latest announcement is out from Carisma Therapeutics ( ($CARM) ). Carisma Therapeutics Inc. announced the voluntary delisting...

9d ago

CARM

Carisma Therapeutics Announces Executive Terminations and Wind-Down

An announcement from Carisma Therapeutics ( ($CARM) ) is now available. Carisma Therapeutics Inc. announced plans to wind...

2M ago

CARM

Insider Moves: Ross, Carisma, Agree, Aehr, Ocular

Insiders have been trading these 5 stocks: (($ROST)), (($CARM)), (($ADC)), (($AEHR)) and (($OCUL)). Here is a breakdown of...

2M ago

ADC

AEHR

Carisma Therapeutics Faces Nasdaq Delisting and Trading Suspension

Carisma Therapeutics ( ($CARM) ) has provided an update. On October 9, 2025, Carisma Therapeutics Inc. received a...

2M ago

CARM

Carisma Therapeutics Amends Agreement with Moderna

An update from Carisma Therapeutics ( ($CARM) ) is now available. On September 16, 2025, Carisma Therapeutics Inc....

3M ago

CARM

Why Is Carisma Therapeutics Stock (CARM) Up 165% Today?

Carisma Therapeutics stock rallied on Tuesday after the company announced an update to its merger with OrthoCellix. ...

3M ago

CARM

OCGN

Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!

Investors are back in the saddle after an extended weekend, and there’s plenty of stock market news to catch up on. ...

3M ago

AMD

BLK

Carisma Therapeutics Announces Merger with OrthoCellix

The latest announcement is out from Carisma Therapeutics ( ($CARM) ). On August 29, 2025, Carisma Therapeutics Inc....

4M ago

CARM

Carisma Therapeutics Approves Reverse Stock Split

The latest update is out from Carisma Therapeutics ( ($CARM) ). On August 5, 2025, Carisma Therapeutics Inc....

4M ago

CARM

Carisma Therapeutics Transfers Listing to Nasdaq Capital Market

Carisma Therapeutics ( ($CARM) ) just unveiled an announcement. On January 6, 2025, Carisma Therapeutics was notified by...

5M ago

CARM

Carisma Therapeutics, OrthoCellix enter definitive merger agreement

Carisma Therapeutics (CARM) and OrthoCellix, a wholly-owned subsidiary of Ocugen (OCGN), announced that they have entered into a...

6M ago

CARM

OCGN

Carisma Therapeutics price target lowered to $1 from $12 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Carisma Therapeutics (CARM) to $1 from $12 and keeps...

9M ago

CARM

Carisma Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor downgraded Carisma Therapeutics (CARM) to Neutral from Buy without a price target after...

12M ago

CARM

CARM FAQ

What was Carisma Therapeutics’s price range in the past 12 months?

Carisma Therapeutics lowest stock price was $0.03 and its highest was $1.27 in the past 12 months.

What is Carisma Therapeutics’s market cap?

Carisma Therapeutics’s market cap is $2.22M.

When is Carisma Therapeutics’s upcoming earnings report date?

Carisma Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is 38 days ago.

How were Carisma Therapeutics’s earnings last quarter?

Carisma Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.14.

Is Carisma Therapeutics overvalued?

According to Wall Street analysts Carisma Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Carisma Therapeutics pay dividends?

Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here

What is Carisma Therapeutics’s EPS estimate?

Carisma Therapeutics’s EPS estimate is -0.12.

How many shares outstanding does Carisma Therapeutics have?

Carisma Therapeutics has 41,845,078 shares outstanding.

What happened to Carisma Therapeutics’s price movement after its last earnings report?

Carisma Therapeutics reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -2%.

Which hedge fund is a major shareholder of Carisma Therapeutics?

Currently, no hedge funds are holding shares in CARM

Company Description

Carisma Therapeutics

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.